Vyant Bio Inc VYNT Stock Analysis
- PINK
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.19 up $0.01, 7.78% at close Dec 29
Last close · Previous close $0.18
- Market cap
- $1.15MAt the Dec 29 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$0.19up $0.02, 9.30%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.18Dec 28
- Volume19.12KDec 29 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume31.77KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Dec 29 close. Total return includes reinvested dividends.Price change only, without dividends.
| Period | VYNT |
|---|---|
| Short term | |
| 1M | VYNT: up 9.3% |
| 3M | VYNT: up 14.1% |
| YTD | VYNT: down 72.4% |
| 1Y | VYNT: down 72.3% |
| Long term | |
| 3Y | VYNT: down 98.5% −75.6% a year |
| 5Y | VYNT: down 99.5% −65.7% a year |
| 10Y | VYNT: down 100.0% −60.5% a year |
$10,000 invested in VYNT 10 years ago (Dec 27, 2013) would be worth about $1 at the close on , with dividends reinvested.
| Period | VYNT |
|---|---|
| Short term | |
| 1M | VYNT: up 9.3% |
| 3M | VYNT: up 14.1% |
| YTD | VYNT: down 72.4% |
| 1Y | VYNT: down 72.3% |
| Long term | |
| 3Y | VYNT: down 98.5% −75.6% a year |
| 5Y | VYNT: down 99.5% −65.7% a year |
| 10Y | VYNT: down 100.0% −60.5% a year |
$10,000 invested in VYNT 10 years ago (Dec 27, 2013) would be worth about $1 at the close on , not counting dividends.
All-time high
$3,150.00
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Apr 5, 2013.
Stock splits
2
Latest: 1-for-5 on . Share counts adjust after each split.
Both splits
- 1-for-5
- 1-for-30
Valuation
The Dec 29 close compared with the last 12 months of reported results (the four quarters to Dec 31, 2022). Tap a metric to see how it’s calculated. Per-share results and the measures based on them are paused. See the note under the price.
Price-to-earnings (P/E)
Paused
Other valuation measures
- 1.7×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - Price-to-bookPausedBook value as of Dec 31, 2022
See the note under the price. - PEG ratioPausedLast 12 months’ EPS growth
See the note under the price. - −1,246.99%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - −$6.70MAt the Dec 29 close
What it would cost to buy the whole business: the market cap at the Dec 29 close, plus debt, minus cash and short-term investments from the Dec 31, 2022 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own VYNT DCF in Excel. Value Vyant Bio with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q4 FY22, the quarter ended Dec 31, 2022. “Last 12 months” means the four quarters from Jan 1, 2022 to Dec 31, 2022, and balance-sheet figures are as of Dec 31, 2022.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $666.00Kdown 42.0%
- Net income
- −$22.69M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q1 FY21 (Mar 31, 2021) | $203.00K | −$7.37M | Paused See the note under the price. |
| Q2 FY21 (Jun 30, 2021) | $329.00K | −$4.19M | Paused See the note under the price. |
| Q3 FY21 (Sep 30, 2021) | $256.00K | −$4.46M | Paused See the note under the price. |
| Q4 FY21 (Dec 31, 2021) | $360.00K | −$24.85M | Paused See the note under the price. |
| Q1 FY22 (Mar 31, 2022) | $303.00K | −$9.16M | Paused See the note under the price. |
| Q2 FY22 (Jun 30, 2022) | $165.00K | −$5.81M | Paused See the note under the price. |
| Q3 FY22 (Sep 30, 2022) | $152.00K | −$3.46M | Paused See the note under the price. |
| Q4 FY22 (Dec 31, 2022) | $46.00K | −$4.26M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY20 (Dec 31, 2020) | $867.00K | −$8.65M | Paused See the note under the price. |
| FY21 (Dec 31, 2021) | $1.15M | −$40.86M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $666.00K | −$22.69M | Paused See the note under the price. |
Margins
- Gross −51.4%
- Operating −2,389.2%
- Net −3,406.9%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$14.30MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$13.68MLast 12 months
- Capital spending$617.00KLast 12 months
- −2,146.8%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $188.00KLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$188.00KLast 12 months
Balance sheet
- $10.04MAs of Dec 31, 2022
Cash plus short- and long-term marketable securities on the Dec 31, 2022 balance sheet.
- Total debt$2.20MAs of Dec 31, 2022
- Net cash$7.85MAs of Dec 31, 2022
- Book value per sharePausedAs of Dec 31, 2022
See the note under the price. - 3.14As of Dec 31, 2022
Current assets divided by current liabilities on the Dec 31, 2022 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.22As of Dec 31, 2022
Total debt divided by shareholders’ equity on the Dec 31, 2022 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 3 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✓Return on assets improved: passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −144.3%Last 12 months
Over the last 12 months, Vyant Bio lost money: its net loss was 144.3% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −93.0%Last 12 months
Over the last 12 months, Vyant Bio’s net loss was 93.0% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Vyant Bio Inc
Vyant Bio, Inc. (“Vyant Bio” or the “Company”), is an innovative biotechnology company focused on identifying unique biological targets and novel and repurposed therapeutics. Vyant Bio has built a platform of therapeutics seeking to treat neurodevelopmental and neurodegenerative diseases, with current programs targeting Rett Syndrome, CDKL5 Deficiency Disorders, and Parkinson’s Disease. The Company’s approach to drug discovery integrates human-derived biology with artificial intelligence and machine learning technologies to de-risk candidate selection, with the goal of improving the potential effectiveness of drugs discovered earlier in the development cycle. Vyant Bio’s management believes that drug discovery needs to progressively shift to more efficient methods as the widely used models for predicting safe and effective drugs have under-performed, as evidenced by the significant time and cost of bringing novel drugs to market. By combining sophisticated data science capabilities with highly functional human cell derived disease models, Vyant Bio seeks to leverage its current ability to screen and test therapeutic candidates, and create a unique approach to assimilating data that supports decision making iteratively throughout the discovery phase of drug development to identify both novel and repurposed CNS therapeutic candidates.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New Jersey, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- PINK
- Asset type
- Common stock
- Price history since
VYNT news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
VYNT stock FAQ
What is VYNT stock’s price today?
Vyant Bio (VYNT) traded at $0.19 at the close on , up $0.01 (7.78%) from the previous close of $0.18.
If you invested $1,000 in VYNT 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in VYNT on would be worth about $0 at the close on , a total return of −100.0%. The same $1,000 would be worth $5 if invested five years ago and $277 if invested one year ago. Past performance doesn’t predict future returns.
What is Vyant Bio’s market cap?
Vyant Bio’s market capitalization is about $1.1 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $0.19 (how market cap works).
How much revenue does Vyant Bio make?
Vyant Bio reported $666.0 thousand of revenue over the four quarters to , down 42.0% from the twelve months before. In its latest quarter (Q4 FY22, ended ) revenue was $46.0 thousand, down 87.2% from a year earlier.
Is Vyant Bio profitable?
Not over the four quarters to . Vyant Bio reported a net loss of $22.7 million across those four quarters on $666.0 thousand of revenue.
Does VYNT pay a dividend?
Vyant Bio hasn’t paid a dividend in the last twelve months.
What is VYNT’s all-time high?
VYNT’s highest closing price was $3,150.00 on , adjusted for stock splits. At $0.19 at the close on , it is 100.0% below that record.
Has VYNT stock ever split?
Yes, twice: 1-for-30 on ; 1-for-5 on .
How has VYNT stock performed?
Including dividends and measured to the close on , VYNT has returned −72.4% so far this year and −72.3% over the past year, and −99.5% over five years (−65.7% a year). Past performance doesn’t predict future returns.
What sector and industry is Vyant Bio in?
Vyant Bio is in the Healthcare sector and the Biotechnology industry, and is headquartered in New Jersey, USA.
What exchange does VYNT trade on?
Vyant Bio trades on the PINK under the ticker symbol VYNT. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.